Sign In
Buy PBYI
$6.81
-0.170 (-2.44%)
At Close: Jun 03, 2026
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration
06:23pm, Thursday, 25'th Feb 2021
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Returns NERLYNX® Rights in Greater China to Puma Biotechnology as the Two Parties Terminate License Agreement and Settle Arbitration
Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China
04:07pm, Thursday, 25'th Feb 2021
LOS ANGELES & CASTRES, France--(BUSINESS WIRE)--Puma Biotechnology and Pierre Fabre added Greater China to their license agreement. Puma and CANbridge Pharma terminated their Greater China agreement
Puma Biotech (PBYI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
01:41pm, Thursday, 18'th Feb 2021
Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented interim results from its biliary tract cancers cohort of the Phase II SUMMIT “basket” trial at ASCO GI 2021,
Puma Biotechnology to Present at the H.C. Wainwright VIRTUAL BioConnect Conference
04:15pm, Monday, 04'th Jan 2021
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will present a Puma Biotechnology update at H.C. Wainwright's BioConnect VIRTUAL Conference beginning on Jan. 11, 2021 at 6:00 am EST.
Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data
08:19am, Tuesday, 29'th Dec 2020
Puma Biotechnology continues to report encouraging clinical data for its flagship product, NERLYNX. Unfortunately, the commercial numbers continue to remain in purgatory. I take a look at the company'
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Friday, 11'th Dec 2020
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported inducement awards for November 2020 as required by Nasdaq Listing Rule 5635(c)(4) .
Puma Biotechnology Presents Efficacy and Safety Outcomes from the Phase III NALA Trial at the 2020 SABCS
02:00pm, Friday, 11'th Dec 2020
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented efficacy and safety outcomes from the Phase III NALA Trial in a Spotlight Poster at the 2020 Virtual SABCS.
Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS
07:31pm, Wednesday, 09'th Dec 2020
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented final overall survival analysis from its Phase III ExteNET Trial at the 2020 San Antonio Breast Cancer Symposium.
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented updated results from its Phase II SUMMIT trial in a Spotlight Poster at the 2020 San Antonio Breast Cancer Symposium.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 06'th Nov 2020
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported its inducement awards for Oct. 2020 as required by Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology's (PBYI) CEO Alan Auerbach on Q3 2020 Results - Earnings Call Transcript
09:42pm, Thursday, 05'th Nov 2020
Puma Biotechnology's (PBYI) CEO Alan Auerbach on Q3 2020 Results - Earnings Call Transcript
Puma Biotechnology to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference
04:15pm, Tuesday, 03'rd Nov 2020
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO and President of Puma Biotechnology, will provide a corporate update at the Credit Suisse Virtual Healthcare Conference on Nov. 10
Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology
08:10pm, Wednesday, 19'th Aug 2020
A manuscript including results from Puma Biotechnology's CONTROL trial was published in the September 2020 issue of Annals of Oncology.
Puma Bio: A Contrarian Investment That Requires Patience
06:16am, Monday, 17'th Aug 2020
Puma Biotechnology recently reported their Q2 earnings that revealed a huge beat on EPS and revenue, but Puma is still struggling to surpass their Q4 2018 numbers.
